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What is already known on this topic  
 Hypoxic-ischaemic encephalopathy (HIE) is characterized by evolving neurologic 
dysfunction and frequently, systemic multi-organ injury.  
 Hypoglycaemia and hyperglycaemia in infants with HIE are common and are associated 
with unfavourable outcomes. 
What this study adds  
 Early glycaemic profile in infants with moderate-to-severe HIE is associated with both 
the risk of multi-organ dysfunction and outcome of therapeutic hypothermia.  
 In the CoolCap Study, only infants with early hyperglycaemia significantly benefited 
from therapeutic hypothermia. 
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ABSTRACT 
Objective To investigate whether glycaemic profile is associated with multi-organ dysfunction 
and with response to hypothermia after perinatal hypoxic ischaemic encephalopathy (HIE). 
Design Post hoc analysis of the CoolCap Study.  
Setting 25 perinatal centres in UK, USA, and New Zealand during 1999–2002.  
Patients 194/234 (83%) infants of ≥36 weeks' gestation with moderate-to-severe HIE enrolled in 
the CoolCap Study with documented plasma glucose levels and follow-up outcome. 
Intervention Infants were randomised to head cooling for 72 h starting within 6 h of birth, or 
standard care. Plasma glucose levels were measured at pre-determined time intervals after 
randomisation.  
Main outcome measure Unfavourable primary outcome was defined as death and/or severe 
neurodevelopmental disability at 18 months. Glycaemic profile (hypoglycaemia [≤40 mg/dL, 
≤2.2 mmol/L], hyperglycaemia [>150 mg/dL, >8.3 mmol/L], and normoglycaemia) during 12 h 
after randomisation was investigated for association with multi-organ dysfunction, or risk 
reduction of primary outcome after hypothermia treatment.  
Results Hypoglycaemia but not hyperglycaemia was associated with more deranged multi-organ 
function parameters (mean pH 7.23 [SD 0.16] vs 7.36 [0.13], p<0.001; aspartate transaminase 
2101 [2450] vs 318 [516] IU/L, p=0.002; creatinine 1.95 [0.59] vs 1.26 [0.5] mg/dL, p<0.001) 
compared to normoglycaemia. After adjusting for Sarnat stage and 5-min Apgar score, only 
hyperglycaemic infants randomised to hypothermia had reduced risk of unfavourable outcome 
(adjusted risk ratio: 0.80, 95% CI 0.66 to 0.99), whereas hypoglycaemic and normoglycaemic 
infants did not. 
Conclusions Early glycaemic profile in infants with moderate-to-severe HIE may help to 
identify risk of multi-organ dysfunction and response to therapeutic hypothermia. 
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INTRODUCTION 
Perinatal hypoxic ischaemic encephalopathy (HIE) is characterized by evolving neurologic 
dysfunction and frequently, systemic multi-organ injury.1, 2 Mild hypothermia induced within 6 h 
of birth for near term and term infants with moderate-to-severe HIE improves survival without 
disability, and the benefits persist to school age.3-6 In the absence of a sentinel event, however, 
the timing, duration, and chronicity of fetal hypoxia-ischaemia remain uncertain. Universal 
application of therapeutic hypothermia, without consideration for the heterogeneous 
pathophysiologic mechanisms of injury, may be suboptimal, as many treated infants with 
moderate-to-severe HIE still die or survive with severe neurodevelopmental and cognitive 
impairment.7 This emphasises the importance of investigating whether laboratory and clinical 
parameters can be identified early after birth, to predict the response to hypothermia treatment, 
and perhaps to guide the choice of individualised adjuvant neuroprotective therapies based on 
specific underlying pathophysiology among this heterogeneous population. 
Glucose is the primary substrate for energy metabolism in the newborn brain, and deranged 
glucose homoeostasis may be a biomarker of, or contribute to, neuronal injury and adverse long-
term outcomes.8-12 At birth, the continuous transplacental supply of glucose ends; normal glucose 
homoeostasis then depends on intact multi-organ function and hormonal regulation.13 Given the 
central role of glucose homoeostasis in cell metabolism, potentially early glycaemic status could 
contribute to the risk of multi-organ injury and recovery in HIE.14  
We previously reported that early deranged glucose homoeostasis in infants with HIE was 
common, and that compared to normoglycaemia, both hypoglycaemia (≤40 mg/dL, ≤2.2 
mmol/L) and hyperglycaemia (>150 mg/dL, >8.3 mmol/L) were associated with greater risk 
(adjusted odds ratio [aOR] 6.2 and 2.7, respectively) of unfavourable outcome at 18 months.15, 16 
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In the current study, we examined the hypotheses first, that early glycaemic perturbations (i.e., 
hypoglycaemia and hyperglycaemia) are biomarkers for the severity, chronicity, and timing of 
perinatal hypoxia-ischaemia and so would be associated with risk of multi-organ dysfunction, 
and second, that glycaemic status would be associated with  benefit from therapeutic 
hypothermia. We reanalysed the CoolCap Study cohort using a different statistical approach, 
exploring the laboratory and clinical characteristics of infants by their early glycemic profile 
(hypoglycaemia, hyperglycaemia, and normoglycaemia within the first 12 h after 
randomization), to investigate for associations with multi-organ dysfunction. We then evaluated 
whether glycaemic status was associated with the outcome of therapeutic hypothermia for the 
primary outcome of death and/or severe disability at 18 months of age. 
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METHODS 
Participants 
The CoolCap Study was a multicentre randomised controlled trial of selective head cooling 
and mild systemic hypothermia for the treatment of perinatal moderate-to-severe HIE in 234 
infants at ≥36 weeks’ gestation enrolled between 1999 and 2002.16 The institutional review board 
of each centre approved the protocol, and subjects were randomised to either head cooling for 72 
h, starting within 6 h of birth, with rectal temperature maintained at 34.5±0.5C, followed by 
rewarming over 4 h, or standard care at 37.0±0.5C. The primary outcome was death or severe 
disability at 18 months (≥1 of the following: gross motor function classification system level 3–
5, Bayley Scales of Infant Development II mental developmental index <70, and/or bilateral 
cortical visual impairment). In this post hoc analysis, subjects lost to follow-up (n=16), those 
with undocumented glucose values (n=4), infants missing Sarnat stage at randomisation (n=4), 
infants diagnosed with Sarnat stage 1 HIE at randomisation (n=8), or those who had both 
hypoglycaemia and hyperglycaemia during the first 12 h (n=8) were excluded.17 Therefore, our 
analyses included 194 of the 234 (83%) infants enrolled in the original CoolCap Study (figure 1). 
Data collected 
Plasma glucose levels, collected at pre-specified time points (0, 4, 8, and 12 h after 
randomisation) were used to classify infants into three groups based on their glycaemic profile 
during the first 12 h after randomisation: (1) hypoglycaemia (≥1 glucose level ≤40 mg/dL, ≤2.2 
mmol/L),18 (2) hyperglycaemia (≥1 glucose level >150 mg/dL, >8.3 mmol/L),11 and (3) 
normoglycaemia (all glucose levels >40 to ≤150 mg/dL, >2.2 to ≤8.3 mmol/L).15 Demographic 
and perinatal data, postnatal clinical and laboratory parameters of multi-organ function (collected 
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at pre-specified time points), and follow-up neurodevelopmental outcome data were retrieved 
from the original records. In the CoolCap Study, infants were randomised at a median of 4.8 
(IQR 4.1 to 5.3) h after birth. For the purposes of our analyses, time points refer to time elapsed 
after randomisation. 
Statistical Analysis 
Descriptive statistics were used to examine demographic, obstetric, and neonatal parameters 
in the entire cohort and then stratified by 12-h glycaemic profile (hypoglycaemia, 
hyperglycaemia, and normoglycaemia). Differences among the three groups were assessed with 
chi-square or Freeman-Halton tests for categorical variables; and ANOVA, Kruskal-Wallis, or 
multi-sample median (Brown-Mood) tests for continuous variables. Multivariable log-binomial 
regression models were used to generate adjusted risk ratios (aRR) and 95% CI for the treatment 
effect (i.e., impact of hypothermia therapy on the risk of an unfavourable outcome at 18 months). 
Each model was adjusted for Sarnat stage and 5-minute Apgar score. An interaction term 
between treatment type (hypothermia vs. standard therapy) and 12-h glycaemic profile was then 
added to determine whether the latter modified the treatment effect observed in the main effects 
model. In addition to relative measures of association, multivariable binomial regression was 
used to estimate adjusted risk differences and the number needed to treat (NNT). Since 
hypothermia could have influenced glycaemic profiles, we performed a sensitivity analysis that 
involved re-running all models using glycaemic profiles at 0-h (prior to beginning therapeutic 
hypothermia) as the potential effect modifier. All hypothesis tests were two-sided, and statistical 
significance for the final models was assessed at the 0.05 level. All analyses were performed 
using SAS 9.4 (SAS Institute, Cary, NC).  
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RESULTS 
Early glycaemic profile and baseline characteristics 
During the first 12 h, 9% (18/194) of infants had ≥1 episode of hypoglycaemia, 45% 
(87/194) had ≥1 episode of hyperglycaemia, and 46% (89/194) were normoglycaemic. 
Demographic and perinatal data stratified by 12-h glycaemic profiles are shown in table 1. 
Mothers of hyperglycaemic infants had higher rates of sentinel delivery complications (i.e., 
prolapsed cord, umbilical cord tear, placental abruption, and ruptured uterus) and emergency 
caesarean deliveries compared to normoglycaemic and hypoglycaemic infants. The distribution 
of glycaemic profile among therapeutic hypothermia and control infants was not statistically 
different (p=0.12, data not shown). 
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Table 1 Baseline infant and maternal characteristics according to glycaemic profile 
Characteristics 
n (%) unless otherwise stated 
All subjects 
(n=194) 
Normoglycaemia 
(n=89) 
Hypoglycaemia 
(n=18) 
Hyperglycaemia 
(n=87) 
p Valuea  
Infant       
  Birth weight, mean (SD), g 3,470 (651) 3,438 (658) 3,416 (658) 3,513 (648) 0.81 
  Gestational age, mean (SD), wks 39.1 (1.5) 39.0 (1.5) 38.8 (1.8) 39.3 (1.5) 0.35 
  Male gender, n (%) 102 (53) 38 (43) 13 (72) 51 (59) 0.02  
  White race, n (%) 126 (65) 61 (69) 9 (50) 56 (64) 0.57 
  Apgar 5-min, median (IQR) 2.0 (0-4.0) 2.5 (0-3.0) 2.0 (0-4.0) 2.0 (0-3.0) 0.80 
  Apgar 5-min >3, n (%) 48 (25) 21 (24) 8 (44) 19 (22) 0.14 
  pH <1 hour of life, mean (SD) 6.87 (0.23) 6.89 (0.23) 6.80 (0.18) 6.87 (0.24) 0.35 
  Sarnat stage 3 at randomisation, n (%) 70 (36) 28 (32) 8 (44) 34 (39) 0.42 
  Hypothermia treatment, n (%) 99 (51) 47 (53) 5 (28) 47 (54) 0.12 
Maternal      
  Age, mean (SD), years 28.4 (6) 28.7 (6) 25.7 (7) 28.7 (7) 0.15 
  First child, n (%) 102 (53) 55 (62) 11 (61) 36 (41) 0.03 
  Gestational diabetes, n (%) 11 (6) 6 (7) 1 (6) 4 (5) 0.90 
  Preeclampsia/eclampsia, n (%) 14 (7) 7 (8) 1 (6) 6 (7) 0.99 
  Antibiotic therapy/pyrexia, n (%) 39 (20) 21 (24) 3 (17) 15 (17) 0.56 
  Emergency caesarean delivery, n (%) 132 (68) 50 (56) 12 (67) 70 (81) 0.002 
  Sentinel delivery complications, n (%)b 69 (36) 26 (29) 4 (22) 39 (45) 0.05 
  Other perinatal complications, n (%)c 42 (22) 23 (26) 2 (11) 17 (20) 0.34 
ap Value from chi-square or Freeman-Halton tests for categorical variables, and ANOVA, Kruskal-Wallis, or multi-sample 
median (Brown-Mood) tests for continuous variables. 
bProlapsed cord, umbilical cord tear, placental abruption, and ruptured uterus. 
cUmbilical cord knot, shoulder dystocia, feto-maternal bleeding, antepartum haemorrhage, traumatic instrument delivery, and 
head entrapment. 
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Univariate analysis of multi-organ function by glycaemic profile 
Acid-base balance 
Infants with hypoglycaemia during the first 12 h after randomisation were more acidotic at 
the time of randomization and at 12 h than normoglycaemic and hyperglycaemic infants (table 
2), with significantly lower pH and bicarbonate levels, and larger base deficits. These parameters 
were not significantly different between hyperglycaemic and normoglycaemic infants. 
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Table 2 Univariate analysis of metabolic and clinical parameters by glycaemic profile 
Metabolic/clinical parameter Normoglycaemia 
(n=89) 
Hypoglycaemia 
(n=18) 
Hyperglycaemia 
(n=87) 
p Valuea 
 n Mean (SD), 
Median (IQR), 
or n (%) 
n Mean (SD), 
Median (IQR), 
or n (%) 
n Mean (SD), 
Median (IQR), 
or n (%) 
Hypo 
vs. 
Norm 
Hyper 
vs. 
Norm 
Hypo 
vs. 
Hyper 
Acid-Base          
pH at 0 h 87 7.36 (0.13) 17 7.23 (0.16) 83 7.34 (0.10) <0.001 0.11 0.005 
pH at 12 h 84 7.41 (0.07) 15 7.30 (0.13) 82 7.39 (0.08) 0.002 0.22 0.01 
HCO3 at 0 h (mEq/L) 77 19.4 (7.7) 15 13.0 (5.6) 83 17.8 (6.6) <0.001 0.08 0.005 
HCO3 at 12 h (mEq/L) 79 22.0 (4.8) 13 18.4 (5.0) 79 21.7 (5.2) 0.02 0.42 0.07 
Base deficit at 0 h (mEq/L) 86 -5.5 (6.3) 18 -11.1 (9.1) 86 -6.3 (6.4) 0.005 0.15 0.02 
Base deficit at 12 h (mEq/L) 84 -1.8 (4.3) 16 -7.0 (7.5) 83 -2.6 (4.2) 0.006 0.15 0.03 
Liver and coagulation parameters          
AST at 0 h (IU/L) 76 275 (388) 14 878 (801) 79 364 (797) 0.003 0.61 0.004 
AST at 24 h (IU/L) 73 318 (516) 9 2101 (2450) 76 394 (663) 0.001 0.22 0.002 
ALT at 0 h (IU/L) 82 115 (239) 17 341 (376) 79 157 (420) 0.002 0.46 0.006 
ALT at 24 h (IU/L) 79 159 (333) 11 531 (608) 77 136 (233) 0.01 0.97 0.009 
PT at 0 h (sec) 80 18.2 (15.4-25.7) 14 26.1 (21.6-50.5) 75 20.1 (15.6-24.4) 0.02 0.19 0.02 
PT at 24 h (sec) 78 15.4 (13.3-17.6) 10 26.4 (21.0-29.6) 72 15.6 (14.1-19.3) 0.05 0.74 0.04 
PTT at 0 h (sec) 82 45.2 (36.4-62.6) 14 79.5 (44.0-93.2) 78 47.0 (37.0-60.8) 0.08 0.53 0.25 
PTT at 24 h (sec) 79 39.0 (34.4-46.0) 9 44.3 (41.7-53.0) 75 43.0 (33.5-55.9) 0.01 0.20 0.73 
Renal function          
Creatinine at 0 h (mg/dL) 81 1.2 (0.3) 16 1.5 (0.5) 80 1.2 (0.3) 0.02 0.29 0.002 
Creatinine at 24 h (mg/dL) 79 1.3 (0.5) 13 1.9 (0.6) 80 1.3 (0.5) <0.001 0.86 <0.001 
Urine output 24 h (ml/kg/hr) 86 1.7 (1.3) 15 0.6 (0.6) 87 1.5 (1.3) <0.001 0.31 0.001 
Haematologic parameters          
Haematocrit at 0 h (%) 88 47.2 (8.2) 18 48.3 (8.0) 81 46.3 (8.7) 0.64 0.36 0.28 
Haematocrit at 24 h (%) 80 47.3 (8.1) 12 45.2 (9.8) 78 46.9 (6.8) 0.64 0.95 0.74 
Platelets at 0 h (109/L) 83 217 (71) 18 161 (81) 78 204 (81) 0.005 0.33 0.04 
Platelets at 24 h (109/L) 76 200 (71) 12 130 (50) 78 175 (78) 0.007 0.09 0.12 
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Respiratory function          
PaO2 at 0 h (mm Hg) 87 113 (74) 18 103 (107) 87 124 (95) 0.02 0.56 0.13 
PaO2 at 12 h (mm Hg) 84 91 (58) 16 74 (46) 85 87 (36) 0.09 0.87 0.06 
PaCO2 at 0 h (mm Hg) 89 33 (14) 18 31 (10) 87 32 (12) 0.84 0.97 0.98 
PaCO2 at 12 h (mm Hg) 86 35 (8) 16 36 (9) 85 36 (10) 0.74 0.67 0.89 
FiO2 at 0 h (%) 86 51 (29) 16 6 (33) 85 58 (31) 0.21 0.11 0.66 
FiO2 at 12 h (%) 83 37 (25) 13 58 (35) 83 39 (26) 0.05 0.21 0.12 
Cardiovascular function          
Heart rate, mean through 12 h 88 125 (21) 18 144 (22) 87 133 (27) 0.002 0.07 0.08 
Heart rate, mean through 24 h 88 125 (21) 18 144 (22) 87 133 (26) 0.002 0.06 0.08 
Systolic BP, mean through 12 h 88 61 (9) 17 59 (14) 87 65 (10) 0.39 0.01 0.05 
Systolic BP, mean through 24 h 88 61 (8) 17 59 (14) 87 65 (9) 0.44 0.01 0.10 
Diastolic BP, mean through 12 h 88 41 (7) 17 38 (13) 87 44 (8) 0.09 0.02 0.01 
Diastolic BP, mean through 24 h 88 41 (7) 17 38 (12) 87 44 (7) 0.14 0.01 0.02 
MAP, mean through 12 h 88 50 (7) 17 46 (13) 87 53 (8) 0.15 0.02 0.03 
MAP, mean through 24 h 88 49 (7) 17 46 (13) 87 52 (7) 0.18 0.03 0.03 
Volume replacement, first 24 h, n (%) 89 52 (59) 18 12 (67) 87 46 (53) 0.60 0.54 0.31 
Vasopressor given, first 24 h, n (%) 89 46 (52) 18 13 (72) 87 56 (64) 0.13 0.10 0.60 
Central nervous system function          
EEG background at 0 h 89  18  87  0.33 0.82 0.66 
  Best, n (%)  4 (5)  2 (11)  6 (7)    
  Intermediate, n (%)  56 (63)  9 (50)  53 (61)    
  Worst, n (%)  29 (33)  7 (39)  28 (32)    
EEG seizure at 0 h, n (%) 89 57 (64) 18 10 (56) 87 55 (63) 0.60 0.99 0.60 
EEG based prognosis group16 89  18  87  0.25 0.77 0.63 
  Best, n (%)  4 (5)  2 (11)  6 (7)    
  Intermediate, n (%)  67 (75)  11 (61)  62 (71)    
  Worst, n (%)  18 (20)  5 (28)  19 (22)    
Sarnat at 0 h 89  18  87  0.29 0.34 0.79 
  2 (moderate), n (%)  61 (69)  10 (56)  53 (61)    
  3 (severe), n (%)  28 (32)  8 (44)  34 (39)    
Sarnat at 76 h 75  11  76  0.03 0.02 0.29 
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  0/1 (mild), n (%)  18 (24)  4 (36)  15 (20)    
  2 (moderate), n (%)  42 (56)  2 (18)  30 (40)    
  3 (severe), n (%)  15 (20)  5 (46)  31 (41)    
Death or Sarnat stage 3 by 76 h, n (%) 78 18 (23) 16 10 (63) 78 33 (42) 0.005 0.02 0.17 
HUS intracerebral haemorrhage, n (%) 83 2 (2) 15 1 (7) 82 3 (4) 0.40 0.68 0.50 
Anticonvulsant therapy, n (%) 70 65 (93) 16 14 (88) 74 71 (96) 0.61 0.49 0.21 
Primary outcome          
Died or severe disability at 18 months, 
n (%) 
89 44 (49) 18 15 (83) 87 59 (68) 0.009 0.01 0.26 
ap Value from chi-square or Freeman-Halton tests for categorical variables, and ANOVA, Kruskal-Wallis, or multi-sample median (Brown-
Mood) tests for continuous variables. 
HCO3, bicarbonate (blood gas); AST, aspartate aminotransferase; ALT, alanine aminotransferase; PT, prothrombin time; PTT, partial 
thromboplastin time; PaO2, partial pressure of oxygen; PaCO2, partial pressure of carbon dioxide; FiO2, fraction of inspired oxygen; BP, blood 
pressure; MAP, mean arterial pressure; EEG, electroencephalogram; HUS, head ultrasound. 
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Liver function 
Liver enzymes were frequently elevated at randomisation and trended higher during the 24 h 
after randomisation. Aspartate aminotransferase (AST) and alanine transaminase (ALT) levels 
were significantly higher in hypoglycaemic infants compared to normoglycaemic and 
hyperglycaemic infants. AST and ALT levels were not significantly different between 
hyperglycaemic and normoglycaemic infants. Prothrombin time (PT) was significantly higher 
among hypoglycaemic infants; partial thromboplastin time (PTT) showed similar although 
mostly non-significant differences.  
Renal function 
Creatinine levels were frequently elevated at randomisation and increased during the next 24 
h; levels were significantly higher among hypoglycaemic infants. Urine output (ml/kg/h) was 
significantly lower in hypoglycaemic infants during the first 24 h compared to the other 
glycaemic groups. 
Haematologic parameters 
Platelet counts were significantly lower among hypoglycaemic infants compared to 
normoglycaemic and hyperglycaemic infants, but were not significantly different between 
hyperglycaemic and normoglycaemic infants. 
Cardiorespiratory function 
Heart rate was highest among the hypoglycaemic infants, whereas hyperglycaemic infants 
had significantly higher mean arterial blood pressure during the first 24 h. There were no 
statistically significant differences between the glycaemic groups for partial pressure of oxygen 
and carbon dioxide. 
Central nervous system function 
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Amplitude-integrated electroencephalogram (aEEG) parameters, Sarnat stage at 
randomisation, cranial ultrasound abnormalities, and the percentage of infants who received 
anticonvulsants were not significantly different between the glycaemic groups. 
Primary outcome 
The rate of death and/or severe neurological disability at 18 months (the primary outcome) 
was higher for hypoglycaemic (83%) and hyperglycaemic (68%) infants, compared to 
normoglycaemic (49%) infants.  
Treatment effect by glycaemic profile 
In the entire cohort, the rate of death or severe neurological disability at 18 months was lower 
among infants who were cooled (55%) compared to those who received standard therapy (67%) 
(table 3). After adjusting for Sarnat stage at randomisation and 5-min Apgar score, hypothermia 
therapy conferred a 23% relative risk reduction (aRR 0.77, 95% CI 0.63 to 0.94). After observing 
significant effect modification of hypothermia treatment, we investigated the treatment effect 
separately within each of the 12-h glycaemic profile groups. Only among hyperglycaemic infants 
did hypothermia therapy confer a statistically significant lower risk of the primary adverse 
outcome (aRR 0.80, 95% CI 0.66 to 0.99), with a 22% absolute risk reduction, and one case of 
death or severe disability at 18 months was averted for about every five hyperglycaemic infants 
who were cooled (NNT = 5). There were no statistically significant reductions in risk of the 
unfavourable primary study outcome associated with hypothermia therapy among 
normoglycaemic (aRR 0.95, 95% CI 0.70 to 1.27) or hypoglycaemic infants (aRR 1.03, 95% CI 
0.52 to 2.00). Sensitivity analysis for differential treatment response of hypothermia in infants 
with glycaemic profiles based on the 0 h glucose values alone were similar, with statistically 
significant risk reduction only in hyperglycaemic infants (aRR 0.76, 0.58 to 0.99). Infants with 
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normoglycaemia (aRR 0.85, 0.61 to 1.18) and hypoglycaemia (aRR 0.92, 0.32 to 2.67) at 0 h did 
not significantly benefit from hypothermia treatment. 
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Table 3 Effect of hypothermia therapy on risk of death and/or severe neurological disability at 18 months 
 Rate of primary outcome Relative differencea in risk Absolute differencea in risk NNTb 
Group 
Cooled 
n/total (%) 
Not cooled 
n/total (%) 
Unadjusted 
RR (95% CI) 
aRR (95% CI) Unadjusted 
RD (95% CI) 
aRD (95% CI) 
Overall 54/99 (55) 64/95 (67) 0.81 (0.64 to 1.02) 0.77 (0.63 to 0.94) -13% (-26 to 1) -16% (-28 to -3) 7 
12-h Glucose profile        
 Normoglycaemia 23/47 (49) 21/42 (50) 0.98 (0.64 to 1.49) 0.95 (0.70 to 1.27) -1% (-22 to 20) -5% (-26 to 16) 100 
 Hypoglycaemia 4/5 (80) 11/13 (85) 0.95 (0.58 to 1.55) 1.03 (0.52 to 2.00) -5% (45 to 36) 1% (-53 to 55) n/a 
 Hyperglycaemia 27/47 (58) 32/40 (80) 0.72 (0.54 to 0.96) 0.80 (0.66 to 0.99) -23% (-41 to -4) -22% (-39 to -4) 5 
aThe reference group consists of infants that are “not cooled” for all relative risk and risk difference models. 
bThe NNT is calculated from the adjusted risk difference point estimate and presents the number of infants that would have to be cooled in 
order to prevent 1 unfavourable 18-month outcome. The NNT is rounded to the next highest whole integer. The NNT is not estimated for the 
hypoglycaemia group since the point estimate does not reflect a risk reduction conferred by hypothermia therapy. 
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DISCUSSION 
In this post hoc analysis of the CoolCap Study, we observed that early postnatal glycaemic 
profile (during the first 12 h after randomisation) was associated both with greater risk of 
deranged multi-organ function and with the response to induced hypothermia in infants with 
moderate-to-severe HIE. We have previously shown in the CoolCap study that the rate of death 
or severe neurological disability at 18 months age was lowest in normoglycaemic infants, 
intermediate in hyperglycaemic infants, and highest in hypoglycaemic infants.15 Consistent with 
this pattern, in the current study we observed that multi-organ dysfunction, as defined by 
deranged laboratory results and clinical status was most severe in hypoglycaemic infants, 
intermediate in hyperglycaemic infants, and lowest in normoglycaemic infants. For the first time, 
this study shows that hyperglycaemic infants from the CoolCap Study benefitted significantly 
from hypothermia treatment, whereas hypoglycaemic and normoglycaemic infants showed no 
apparent benefit.  
Therapeutic hypothermia and proposed adjuvant agents such as erythropoietin, xenon, 
melatonin have distinct neurotrophic, anti-apoptotic, anti-inflammatory, and anti-oxidant 
mechanisms that may contribute to their role in neuroprotection.19-23 We speculate that 
individualised treatment with hypothermia plus specific adjuvant therapies directed to distinct 
pathophysiologic categories of infants with HIE may allow more optimal treatment than 
hypothermia alone.  
Previous clinical studies have reported associations between deranged glucose homoeostasis 
and outcomes in infants with HIE.11, 12, 18, 24-26 While we proposed a rather simplistic hypothesis 
that the severity, chronicity, and temporal pattern of perinatal hypoxia-ischaemia influences 
postnatal glycaemic profile, multi-organ dysfunction, and the response to hypothermia treatment, 
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it is important to appreciate that the aetiology and pathogenesis of deranged glucose 
homoeostasis in the setting of HIE are likely to be multifactorial, and its role as a biomarker of 
the underlying process or as a direct contributor to neuronal injury is not clearly understood.  
Potentially, early hypoglycaemia may represent a category of HIE in which infants have 
depleted fetal energy reserves and decreased gluconeogenesis secondary to liver dysfunction. 
This could be related for example to more prolonged exposure to fetal hypoxia-ischaemia. 
Consistent with this sub-hypothesis, watershed–predominant lesions are more common in infants 
with HIE who have severe hypoglycaemia, and this pattern of injury has been associated with 
prolonged partial asphyxia.27-29 Perhaps, many infants with moderate-to-severe HIE with severe 
multi-organ dysfunction (identified by early hypoglycaemia) are beyond the temporal therapeutic 
window or too severely injured to benefit from therapeutic hypothermia. 
Early hyperglycaemia may represent another category of HIE, in which infants have milder 
multi-organ injury with intact gluconeogenesis and stress hormone responses, but have decreased 
glucose utilisation due to selective brain injury from perinatal asphyxia.30, 31 In view of the 
retrospective nature of this analysis it is not possible to assess the impact, if any, of clinical 
glucose management; however, hyperglycaemia may occur during standard newborn glucose 
infusion rates. Speculatively, it is possible that the fetal hypoxic-ischaemic insult in at least some 
hyperglycaemic infants was temporally acute but relatively intense, consistent with the finding 
that this group had the highest rate of sentinel complications and emergency caesarean delivery. 
This would suggest that the evolution of brain injury in some hyperglycaemic infants may have 
been more likely to be within the therapeutic window for hypothermia to be beneficial. 
Normoglycaemic infants, by contrast, had the least multi-organ dysfunction, had the lowest 
proportion of Sarnat stage 3 HIE at randomisation, and had the best outcomes. It is unclear why 
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this most stable group, with the best outcomes did not seem to benefit from therapeutic 
hypothermia. Analysis of other research cohorts in a meta-analysis is essential to confirm this 
finding. 
Hypothermia itself may influence the glycaemic profile as noted by higher glucose levels at 
4–24 h after randomisation in cooled infants in the original CoolCap Study cohort.16 We 
therefore investigated the association of glycaemic profiles at 0 h (before hypothermia) with 
treatment response, and found similar and statistically significant benefits of hypothermia for 
hyperglycaemic infants only. This reinforces that early glycaemic profiles may represent distinct 
groups of infants with HIE, and are not confounded by treatment with hypothermia.  
Some limitations of the present post hoc analysis should be considered. We do not have 
glucose values between the pre-specified time points or continuous values. The study, however, 
is strengthened by the determination of glucose and other metabolic and clinical parameters at 
pre-defined, discrete time points that were independent of clinical decisions. Glucose infusion 
rates, treatment thresholds, and interventions used were not standardised across centres, and 
variations in practice may have influenced the results. We also do not have information on the 
source (arterial, venous, or capillary) of all blood samples, laboratory test protocols, and 
monitoring devices, which may affect interpretation of our findings. Assessment of subsequent 
brain injury was limited because continuous EEG and MRI were not systematically done at all 
the centres. Further, there were few hypoglycaemic infants and many of them did not receive 
hypothermia, and thus this study had limited power to assess the impact of hypothermia on this 
subgroup.  
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CONCLUSIONS 
Distinct clinical categories may be identified among infants with moderate-to-severe HIE 
based on the early postnatal glycaemic profile. These glycaemic profiles were associated with 
risk of multi-organ injury and with response to hypothermia treatment. Hypoglycaemic infants 
had the most severe multi-organ dysfunction, whereas hyperglycaemic infants had relative 
sparing of systemic organs. Critically, infants with hyperglycaemia appeared to benefit most 
from therapeutic hypothermia. Prospective studies are essential to investigate the role of early 
glycaemic patterns and their potential role in predicting response to therapeutic hypothermia, 
whether these patterns could guide individualised treatment protocols, and finally whether 
controlled euglycaemia could further improve outcomes in infants with moderate-to-severe HIE.   
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Figure legends 
Figure 1 Flow of infants through the trial. 
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Infants assessed for eligibility (n=541) 
Excluded (n= 307) 
 Not meeting inclusion criteria (n= 
271) 
 Declined to participate (n=15) 
 Other reasons (n= 21) 
Randomised to head cooling (n= 116) 
 Received head cooling intervention (n=112) 
 Not cooled (n= 4) 
Randomised to conventional care (n= 
118) 
 1 cooled briefly 
Randomised in CoolCap Study (n= 234) 
Lost to follow-up 
(n=8) 
Lost to follow-up 
(n=8) 
Other exclusions: (n=15) 
 Glucose data unavailable (n=3) 
 Both hypoglycaemia and 
hyperglycaemia within first 12 h (n=6) 
 Sarnat stage=1 (n=3) 
 Sarnat stage missing (n=3) 
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E
n
ro
ll
m
en
t 
 
A
ll
o
ca
ti
o
n
 
 
F
o
ll
o
w
-u
p
 
 
S
ec
o
n
d
a
ry
 a
n
a
ly
si
s 
 
Included conventional care infants 
(n=95) 
Included cooled infants 
(n=99) 
Other exclusions: (n=9) 
 Glucose data unavailable (n=1) 
 Both hypoglycaemia and 
hyperglycaemia within first 12 h (n=2) 
 Sarnat stage=1 (n=5) 
 Sarnat stage missing (n=1) 
 
 
Normoglycaemic infants 
(n=89) 
Infants cooled (n=47) 
Hypoglycaemic infants 
(n=18) 
Infants cooled (n=5) 
Hyperglycaemic infants 
(n=87) 
Infants cooled (n=47) 
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